发明名称 HUMAN IGG1 DERIVED ANTIBODY WITH PRO-APOPTOTIC ACTIVITY
摘要 A method for increasing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody, includes: mutating the human CH1γ1 domain from the antibody, to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or by substituting the human CH1γ1 domain by the CH1 domain from a human IgG2 (CH1γ2), IgG3 (CH1γ3) or IgG4 (CH1γ4); the antibody obtained by such method, includes a) a light chain including the following amino acid sequences: i) the Light Chain Variable Region (LCVR) specific from an antigen; and ii) a human kappa (κ) Constant (CL) domain; and b) a heavy chain including the following amino acid sequences: i) the Heavy Chain Variable Region (HCVR) specific from the antigen; ii) the CH2 and CH3 domains from a human IgG1; and iii) the CH1 domain from a human IgG1, mutated to restore pairing between CH1 and CL domains.
申请公布号 EP3068798(A1) 申请公布日期 2016.09.21
申请号 EP20140823891 申请日期 2014.11.11
申请人 OGD2 PHARMA 发明人 DORVILLIUS, MYLÈNE;LE DOUSSAL, JEAN-MARC;TERME, MICKAËL
分类号 C07K16/00 主分类号 C07K16/00
代理机构 代理人
主权项
地址